title: Protective effects of atorvastatin against oxidized LDL-induced downregulation             of KLF expression in EA.hy926 cells.
abstract: Krüppel-like transcription factors (KLFs) play a key role in both vascular             development and pathophysiological processes, but little is known about the relationship             between KLFs and oxidized low-density lipoprotein (ox-LDL). We investigated the             effects of ox-LDL on KLF expression. Furthermore, since atorvastatin is commonly             used to treat high cholesterol, we also examined the role of this drug in the             regulation of KLF expression. The human umbilical vein endothelial cell line EA.hy926             was treated with atorvastatin and ox-LDL alone or in combination, and KLF expression             was examined by DNA microarray, semi-quantitative real-time PCR, western blot             and immunoﬂuorescence analyses. Atorvastatin upregulated KLF expression in EA.hy926             cells in both the quiescent and ox-LDL-induced inflammatory states, suggesting             that KLFs were novel participants in the vascular endothelial dysfunction response             to ox-LDL. Our study demonstrated that atorvastatin increased both the mRNA and             protein levels of KLF in quiescent EA.hy926 cells. Moreover, atorvastatin counteracted             the ox-LDL-induced downregulation of KLF expression.
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital,                     Beijing 100853, P.R. China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Gao
authors.forename: Xian-Feng
authors.initials: XF
authors.lastname: Liu
authors.forename: Xue-Chun
authors.initials: XC
authors.lastname: Lu
authors.forename: Cong
authors.initials: C
authors.lastname: Ma
authors.forename: Jian
authors.initials: J
authors.lastname: Cao
authors.forename: Li
authors.initials: L
authors.lastname: Fan
mesh_terms: D000069059:Atorvastatin; D019610:Cytoprotection; D015536:Down-Regulation / Q000187:drug effects* / Q000235:genetics; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D006538:Heptanoic Acids / Q000494:pharmacology*; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D051741:Kruppel-Like Transcription Factors / Q000235:genetics / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D015203:Reproducibility of Results; D016192:Resting Phase, Cell Cycle
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D051741:Kruppel-Like Transcription Factors; D008077:Lipoproteins, LDL; D011758:Pyrroles; C099252:oxidized low density lipoprotein; D000069059:Atorvastatin